Non-small Cell Lung Cancer Treatment Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza), and R

Non-small Cell Lung Cancer Treatment Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza), and Ramucirumab (Cyramza)), and Immunotherapy (Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Others)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cancer is a disease, in which cell grows abnormally and may cause a tumor. In lung cancer, the cells of lungs starts to grow in uncontrolled manner later form a tumor and that can be spread into other body parts. Small cell lung cancer and Non-small cell lung cancer are two main types of lung cancer. According to the stats of Lung Cancer Alliance (leading non-profit organization dedicated to fighting lung cancer), out of overall lung cancer, around 80 to 85% cases found are of Non-small cell lung cancer type and 15-20% cases found are of small cell lung cancer type. Different and commonly diagnosed types of Non-small cell lung cancer (NSCLC) include adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and large cell neuroendocrine tumors. Out of all these types adenocarcinoma and squamous cell carcinoma accounts around 60% of lung cancer.
Market Dynamics
Increasing prevalence of lung cancer is a major factor that is expected to drive growth of the Non-small cell lung cancer treatment market. Non-small cell lung cancer is the leading cause of cancer-related mortality in the U.S. For instance, according to data published by the American Cancer Society, Inc. (ACSI), NSCLC is the second most common type of cancer found in both men and women. Moreover, as per the estimation of ACSI, in 2017, it was estimated that around 222,500 new cases of lung cancer, and 155,870 deaths were reported due to lung cancer in the U.S.
Moreover, the National Cancer Institute estimated that in 2021, around 2 million new cases (or 11% of total cancer cases) of lung cancer were diagnosed in the U.S.
Key features of the study:
This report provides in-depth analysis of the global Non-small cell lung cancer treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global Non-small cell lung cancer treatment market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological upgradation, market expansion, and marketing tactics
The global Non-small cell lung cancer treatment market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for global Non-small cell lung cancer treatment market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Non-small Cell Lung Cancer Treatment Market, by Type:
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors
Global Non-small Cell Lung Cancer Treatment Market, by Treatment:
Chemotherapy
Targeted Therapy
Bevacizumab (Avastin)
Necitumumab (Portrazza)
Ramucirumab (Cyramza)
Immunotherapy
Nivolumab (Opdivo)
Atezolizumab (Tecentriq)
Others
Global Non-small Cell Lung Cancer Treatment Market, by Region:
North America
By Country:
U.S.
Canada
By Type:
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors
By Treatment:
Chemotherapy
Targeted Therapy
Bevacizumab (Avastin)
Necitumumab (Portrazza)
Ramucirumab (Cyramza)
Immunotherapy
Nivolumab (Opdivo)
Atezolizumab (Tecentriq)
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Type:
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors
By Treatment:
Chemotherapy
Targeted Therapy
Bevacizumab (Avastin)
Necitumumab (Portrazza)
Ramucirumab (Cyramza)
Immunotherapy
Nivolumab (Opdivo)
Atezolizumab (Tecentriq)
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Type:
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors
By Treatment:
Chemotherapy
Targeted Therapy
Bevacizumab (Avastin)
Necitumumab (Portrazza)
Ramucirumab (Cyramza)
Immunotherapy
Nivolumab (Opdivo)
Atezolizumab (Tecentriq)
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Type:
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors
By Treatment:
Chemotherapy
Targeted Therapy
Bevacizumab (Avastin)
Necitumumab (Portrazza)
Ramucirumab (Cyramza)
Immunotherapy
Nivolumab (Opdivo)
Atezolizumab (Tecentriq)
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Type:
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors
By Treatment:
Chemotherapy
Targeted Therapy
Bevacizumab (Avastin)
Necitumumab (Portrazza)
Ramucirumab (Cyramza)
Immunotherapy
Nivolumab (Opdivo)
Atezolizumab (Tecentriq)
Others
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Type:
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors
By Treatment:
Chemotherapy
Targeted Therapy
Bevacizumab (Avastin)
Necitumumab (Portrazza)
Ramucirumab (Cyramza)
Immunotherapy
Nivolumab (Opdivo)
Atezolizumab (Tecentriq)
Others
Company Profiles
Pfizer Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
AstraZeneca plc
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Boehringer Ingelheim GMBH
Novartis AG
Bristol-Myers Squibb Company
Merck & Co., Inc.

“*” marked represents similar segmentation in other categories in the respective section.